Jody Piltz Seymour, MD
Ophthalmology · Huntingdon Valley, PANPI 1144213372
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $186,239 of the $246,286 with a category attached, or 75.6%. Aerie Pharmaceuticals, Inc. accounts for 63.5% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $70,375 and has fallen 75.1% since, to $17,525 in 2025. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $1578.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$156K
- Alcon$42K
- Alcon Research LLC$31K
- Boehringer Ingelheim International GmbH$14K
- AbbVie$3K
- Bausch & Lomb Americas Inc.$173
- plus $583 from 11 others
Across 5 payments — averaging $9100.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aerie Pharmaceuticals, Inc.$46K
What the payments were for
- Consulting fees$186,23976%
- Speaking & faculty fees$48,32520%
- Travel & lodging$7,9123%
- Food & beverage$3,7742%
- Gifts$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 88 | $156,381 |
| Alcon | 29 | $41,920 |
| Alcon Research LLC | 6 | $30,712 |
| Boehringer Ingelheim International GmbH | 2 | $13,813 |
| AbbVie(2 entities) | 8 | $2,705 |
| Bausch & Lomb Americas Inc. | 4 | $173 |
| Sun Pharmaceutical Industries Inc. | 5 | $171 |
| Tarsus Pharmaceuticals, Inc. | 2 | $154 |
| Notal Vision, Inc. | 1 | $70 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $53 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $37 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $18 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Sight Sciences, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| Omeros Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$192,155
- Rhopressa$158,567
- SIMBRINZA$8,530
- ALPHAGAN P$1,300
- Hydrus Microstent$175
- XEN GLAUCOMA TREATMENT SYSTEM$143
- VYZULTA$128
- AcrySof IQ PanOptix$106
- BROMSITE$106
- CEQUA$106
- XDEMVY$102
How this compares
$246,286 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 331 | $159,567 |
| RhopressaNetarsudil Mesylate | 175 | $74,384 |
| RocklatanNetarsudil Mesylat/Latanoprost | 92 | $53,194 |
| Phospholine IodideEchothiophate Iodide | 12 | $29,954 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 84 | $27,171 |
| Timolol Maleate | 304 | $25,425 |
| Alphagan PBrimonidine Tartrate | 54 | $24,999 |
| Brinzolamide | 74 | $20,435 |
| RestasisCyclosporine | 14 | $20,118 |
| CombiganBrimonidine Tartrate/Timolol | 43 | $15,201 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 64 | $12,462 |
| AzoptBrinzolamide | 20 | $11,100 |
| VyzultaLatanoprostene Bunod | 18 | $11,093 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 45 | $10,044 |
| Brimonidine Tartrate | 130 | $9,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Restasis, Combigan | $2,705 | $219,886442 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $156,381 | $127,578267 claims |
| AlconSimbrinza, Azopt | $41,920 | $38,271104 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $173 | $11,09318 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $53 | $2,12516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Huntingdon Valley
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
- David AlmeidaErie$734K
- Carl RegilloPlymouth Meeting$721K
- Robert NoeckerPittsburgh$632K
- Beeran MeghparaPhiladelphia$496K
- Michael KlufasPlymouth Meeting$393K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.